Non Vascular Stent Market Expected to Reach $2.7 Billion by 2035

According to a new report published by Allied Market Research, titled, “Non Vascular Stent Market," The non vascular stent market size was valued at $1.6 billion in 2023, and is estimated to reach $2.7 billion by 2035, growing at a CAGR of 4.5% from 2024 to 2035.

A non vascular stent is a medical device designed to provide support and maintain the patency of non vascular lumens or passageways in the body. These stents are used in various systems, including the gastrointestinal, biliary, urinary, and respiratory tracts, to treat obstructions or stenosis caused by conditions such as tumors, inflammation, or scarring. Constructed from materials such as metal alloys, polymers, or biodegradable substances, non vascular stents are available in self-expanding, balloon-expandable, and drug-eluting forms. They are typically placed using minimally invasive procedures under endoscopic or fluoroscopic guidance. Non vascular stents improve patient outcomes by alleviating symptoms such as pain, obstruction, or impaired organ function, and are integral to managing both benign and malignant conditions affecting non vascular channels.

Rise in prevalence of chronic diseases is a significant driver for the non vascular stent market growth, as conditions like gastrointestinal disorders, respiratory diseases, and cancers frequently cause blockages that require stent placement. As these diseases become more common globally, the demand for stent-based interventions increases, particularly among the aging population. In addition, rise in awareness about non vascular stents is driving market expansion, as patients and healthcare providers recognize the benefits of these devices in managing chronic conditions effectively. Awareness campaigns, along with improved access to information, have resulted in higher patient adoption of stent treatments.

Moreover, favorable reimbursement policies further enhance the non vascular stent market growth by reducing financial barriers to treatment. Comprehensive reimbursement structures ensure that patients can access necessary procedures without facing out-of-pocket expenses. These policies also encourage healthcare providers to adopt advanced stent technologies, knowing that they will be reimbursed for their services. As more countries implement favorable reimbursement frameworks, the non vascular stents become more affordable, thus driving the market demand.

Initiatives by key non vascular stent industry players are significantly accelerating non vascular stent market opportunity. For example, in March 2021, AMG International GmbH, a subsidiary of Q3 Medical Devices Limited, strengthened its leadership in biodegradable implant development. The company received CE Mark approval for its UNITY-B balloon-expandable biodegradable biliary stent (BEBS), designed for endoscopic use. This new product complements the ARCHIMEDES biodegradable pancreaticobiliary stent, the world’s first CE-approved biodegradable implant. The UNITY-B, alongside ARCHIMEDES, offers a range of degradation profiles, including fast, medium, and long-lasting options, addressing varying clinical needs. Such innovations from leading players contribute to the market growth by offering more effective, patient-friendly alternatives to traditional stents.

The non vascular stent industry is segmented into product type, material type, end user, and region. On the basis of product type, it is segmented into gastrointestinal stents, pulmonary (airway) stents, urological stents, and others. urological stents segment dominated the market share in 2023. This was attributed to the rising prevalence of urological disorders such as kidney stones, ureteral strictures, and benign prostatic hyperplasia (BPH). The increasing adoption of minimally invasive procedures, advancements in stent design improving biocompatibility and durability, and growing awareness among healthcare professionals further contributed to its market leadership.
 
However, the pulmonary (airway) stents segment is expected to register the highest CAGR during the forecast period owing to rise in prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD) and tracheal stenosis. Rise in adoption of minimally invasive treatments, rise in awareness of airway management solutions, and advancements in stent designs tailored for respiratory applications further drive the segment growth.

On the basis of material type, the market is divided into metallic stents, and non-metallic stents. The non-metallic stents segment dominated the non vascular stent market share in 2023, owing to rise in demand for biodegradable and polymer-based stents, which minimize long-term complications like inflammation and migration. Their ability to provide temporary support without requiring removal appeals to both patients and providers. Increased focus on patient-centric care, coupled with advancements in material technology and expanding applications, further accelerates the adoption of non-metallic stents.

On the basis of end user, it is classified into hospitals, ambulatory surgical centers, and others. The hospitals segment dominated the non vascular stent market share in 2023, owing to their advanced infrastructure, specialized medical staff, and ability to perform complex procedures, including stent placement, with high precision. Hospitals offer a comprehensive range of services and are equipped with the latest technologies for diagnosing and treating conditions requiring non vascular stents. In addition, hospitals provide better access to post-procedure care and management, contributing to their dominance in the market.

However, the others segment is expected to register the highest CAGR during the non vascular stent market forecast period owing to increasing clinical research activities, advancements in stent technologies, and growing collaborations between healthcare institutions and manufacturers. Specialty clinics offer specialized treatments, driving demand for advanced stents, while research institutes contribute to innovation and new product development. Additionally, the rising focus on personalized medicine and the increasing number of academic studies on non-vascular stents further support market growth.

Region-wise, North America was the largest shareholder in the non vascular stent market size in 2023, owing to its well-established healthcare infrastructure, advanced medical technology, and high healthcare expenditure. The presence of leading market players, favorable reimbursement policies, and rise in aging population contributed to the region's dominance. In addition, North America's strong research and development capabilities, along with high awareness on availability of non vascular stents and adoption of minimally invasive procedures, fueled the non vascular stent market trends.

However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period owing to the region's rapidly growing healthcare infrastructure, rise in prevalence of chronic diseases, and increase in demand for minimally invasive treatments. The aging population, coupled with rise in awareness and affordability of advanced medical technologies, drives market adoption. In addition, government initiatives to expand healthcare access and investments in medical device innovation are expected to further accelerate the market growth in the region.

Key findings of the study

• On the basis of product type, the urological stents segment dominated the market share in 2023. However, the pulmonary (airway) stents segment is anticipated to grow at the highest CAGR during the forecast period. 
• On the basis of material type, the non-metallic stents segment dominated the market share in 2023 and is anticipated to grow at the highest CAGR during the forecast period. 
• On the basis of end user, the hospitals segment dominated the market share in 2023. However, the others segment is anticipated to grow at the highest CAGR during the forecast period. 
• Region wise, North America generated the largest revenue in 2023. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period